Trials / Completed
CompletedNCT00792350
INSIGHT - Post Marketing Surveillance
International Study With Nexavar About Safety and Efficacy in Carcinoma Hepatocellular Therapy (HCC)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 791 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this international non-interventional post-marketing surveillance study we want to evaluate patient characteristics in HCC patients as well as efficacy and safety of Sorafenib (Nexavar®) treatment under daily-life treatment conditions. Specifically investigated are the tumor status, prior and/ or concomitant surgical, radiological and drug treatment and the duration of Sorafenib treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib (Nexavar, BAY43-9006) | Treatment of Hepatocellular Carcinoma with Nexavar (HCC) |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2013-10-01
- Completion
- 2014-04-01
- First posted
- 2008-11-17
- Last updated
- 2014-05-14
Locations
2 sites across 2 countries: Austria, Germany
Source: ClinicalTrials.gov record NCT00792350. Inclusion in this directory is not an endorsement.